Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review.

Abstract

PURPOSE:

The natural history of pleomorphic lobular carcinoma in situ (PLCIS) remains largely unknown.

METHODS:

A pathology database search (1995-2012) was performed to identify patients diagnosed with an LCIS variant. Patients with synchronous breast cancer and/or no evidence of pleomorphism were excluded. Original slides were re-evaluated by three pathologists to identify a consensus cohort of PLCIS. Borderline lesions with focal atypia were classified as LCIS with pleomorphic features (LCIS-PF). Clinical data were obtained from medical records.

RESULTS:

From 233 patients, we identified 32 with an LCIS variant diagnosis and no concurrent breast cancer. Following review, 16 cases were excluded due to lack of pleomorphism. The remaining 16 were classified as PLCIS (n = 11) and LCIS-PF (n = 5). 12/16 patients were treated with surgical excision ± chemoprevention. Patients with a prior breast cancer history and those having mastectomy were excluded from outcome analysis. Among the remaining 7 patients with PLCIS/LCIS-PF, 4/7 (57%) developed ipsilateral breast cancer at a median follow-up of 67 months. Median age at the time of breast cancer diagnosis was 56 years old and median time from PLCIS/LCIS-PF to cancer diagnosis was 59 months (range 45-66 months). The four cancers included 1 invasive lobular carcinoma (ILC), 1 microinvasive ILC, 1 invasive ductal carcinoma, and 1 ductal carcinoma in situ.

CONCLUSIONS:

We confirm that PLCIS in isolation is indeed a rare entity, further contributing to the difficulty in determining the actual risk conferred by this lesion. Long-term follow-up data on larger cohorts are needed to define standardized management and outcomes for patients with PLCIS.

• Authors: Marina De Brot, Starr Koslow Mautner, Shirin Muhsen, Victor P Andrade, Anita Mamtani, Melissa Murray, Dilip Giri, Rita A Sakr, Edi Brogi, Tari A King
• Journal: Breast cancer research and treatment (Breast Cancer Res Treat) Vol. 165 Issue 2 Pg. 411-420 (Sep 2017) ISSN: 1573-7217 [Electronic] Netherlands
• PMID: 28612228 (Publication Type: Journal Article)

Chemical References

• Biomarkers, Tumor

Topics

• Adult
• Aged
• Biomarkers, Tumor
• Biopsy
• Breast Carcinoma In Situ (diagnosis, pathology, therapy)
• Carcinoma, Lobular (diagnosis, pathology, therapy)
• Combined Modality Therapy
• Databases, Factual
• Female
• Follow-Up Studies
• Humans
• Immunohistochemistry
• Middle Aged
• Multimodal Imaging (methods)